Back to Search
Start Over
Nicotine-mediated therapy for Parkinson's disease in transgenic Caenorhabditis elegans model.
- Source :
- Frontiers in Aging Neuroscience; 2024, p01-16, 16p
- Publication Year :
- 2024
-
Abstract
- Parkinson's disease resultant in the degeneration of Dopaminergic neurons and accumulation of α-synuclein in the substantia nigra pars compacta. The synthetic therapeutics for Parkinson's disease have moderate symptomatic benefits but cannot prevent or delay disease progression. In this study, nicotine was employed by using transgenic Caenorhabditis elegans Parkinson's disease models to minimize the Parkinson's disease symptoms. The results showed that the nicotine at 100, 150, and 200 µM doses reduced degeneration of Dopaminergic neurons caused by 6-hydroxydopamine (14, 33, and 40%), lowered the aggregative toxicity of α-synuclein by 53, 56, and 78%, respectively. The reduction in food-sensing behavioral disabilities of BZ555 was observed to be 18, 49, and 86%, respectively, with nicotine concentrations of 100 µM, 150 µM, and 200 µM. Additionally, nicotine was found to enhance Daf-16 nuclear translocation by 14, 31, and 49%, and dose-dependently increased SOD-3 expression by 10, 19, and 23%. In summary, the nicotine might a promising therapy option for Parkinson's disease. [ABSTRACT FROM AUTHOR]
- Subjects :
- THERAPEUTIC use of nicotine
DRUG therapy for Parkinson's disease
PROTEINS
BIOLOGICAL models
DATA analysis
NICOTINE
NEURONS
CHEMICAL reagents
PARKINSON'S disease
TRANSCRIPTION factors
QUANTITATIVE research
IN vivo studies
OXIDATIVE stress
DESCRIPTIVE statistics
PLANT extracts
GENE expression
MOLECULAR structure
ANALYSIS of variance
STATISTICS
CAENORHABDITIS elegans
DOPAMINE
DATA analysis software
Subjects
Details
- Language :
- English
- ISSN :
- 16634365
- Database :
- Complementary Index
- Journal :
- Frontiers in Aging Neuroscience
- Publication Type :
- Academic Journal
- Accession number :
- 177541587
- Full Text :
- https://doi.org/10.3389/fnagi.2024.1358141